STERIS (STE) to Release Earnings on Wednesday

STERIS (NYSE:STE) is expected to announce its Q3 2026 results after the market closes on Wednesday, February 4th. Analysts expect the company to announce earnings of $2.53 per share and revenue of $1.4812 billion for the quarter. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. Investors can find conference call details on the company’s upcoming Q3 2026 earning report page for the latest details on the call scheduled for Thursday, February 5, 2026 at 9:00 AM ET.

STERIS (NYSE:STE) last announced its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.38 by $0.09. The firm had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. STERIS had a return on equity of 14.43% and a net margin of 12.07%.During the same quarter in the previous year, the business earned $2.14 EPS. On average, analysts expect STERIS to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

STERIS Stock Performance

NYSE:STE opened at $263.34 on Wednesday. The stock has a market capitalization of $25.85 billion, a PE ratio of 37.84 and a beta of 1.03. The company has a fifty day moving average of $259.10 and a two-hundred day moving average of $248.17. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.63 and a current ratio of 2.37. STERIS has a fifty-two week low of $204.90 and a fifty-two week high of $269.44.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $273.50.

Insider Transactions at STERIS

In other STERIS news, VP Julia Madsen sold 5,008 shares of the firm’s stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $262.00, for a total value of $1,312,096.00. Following the transaction, the vice president directly owned 10,710 shares of the company’s stock, valued at $2,806,020. This trade represents a 31.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP John Adam Zangerle sold 15,000 shares of the firm’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $265.14, for a total value of $3,977,100.00. Following the completion of the sale, the vice president directly owned 33,669 shares of the company’s stock, valued at $8,926,998.66. This trade represents a 30.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 25,044 shares of company stock worth $6,586,218 over the last 90 days. 1.07% of the stock is currently owned by company insiders.

Institutional Trading of STERIS

A number of large investors have recently made changes to their positions in the company. Geneos Wealth Management Inc. lifted its position in STERIS by 416.0% in the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 104 shares during the period. Advisory Services Network LLC purchased a new position in shares of STERIS during the 3rd quarter worth approximately $68,000. MUFG Securities EMEA plc purchased a new stake in shares of STERIS in the second quarter valued at approximately $69,000. Brown Brothers Harriman & Co. grew its holdings in STERIS by 51.3% during the third quarter. Brown Brothers Harriman & Co. now owns 528 shares of the medical equipment provider’s stock worth $131,000 after acquiring an additional 179 shares during the period. Finally, Tocqueville Asset Management L.P. purchased a new position in STERIS in the third quarter worth $205,000. 94.69% of the stock is owned by institutional investors and hedge funds.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.